PMID- 29214785
OWN - NLM
STAT- MEDLINE
DCOM- 20180309
LR  - 20181202
IS  - 1976-2437 (Electronic)
IS  - 0513-5796 (Print)
IS  - 0513-5796 (Linking)
VI  - 59
IP  - 1
DP  - 2018 Jan
TI  - Clinical Outcomes of Low-Dose Methotrexate Therapy as a Second-Line Drug for 
      Intravenous Immunoglobulin-Resistant Kawasaki Disease.
PG  - 113-118
LID - 10.3349/ymj.2018.59.1.113 [doi]
AB  - PURPOSE: Intravenous immunoglobulin (IVIG) is the standard treatment for Kawasaki 
      disease (KD). However, there is still no standard treatment for IVIG-resistant 
      KD. This study aimed to evaluate the efficacy of low-dose methotrexate (MTX) as a 
      treatment for IVIG-resistant KD. MATERIALS AND METHODS: We retrospectively 
      analyzed 10-year data for patients with IVIG-resistant KD who were administered 
      MTX at Severance Children's Hospital. RESULTS: The subjects included 75 patients 
      with KD aged 5 months to 9.2 years who had been administered MTX. Their maximum 
      body temperatures decreased significantly within 24 h of therapy. The patients' 
      C-reactive protein levels were significantly lower 1 week after administering the 
      first dose of MTX than those before treatment. No adverse effect for MTX was 
      observed. CONCLUSION: MTX treatment of IVIG-resistant KD resulted in rapid 
      defervescence, improvement of clinical symptoms, and normalization of acute-phase 
      reactants in all patients. Thus, MTX could be a candidate treatment for 
      IVIG-resistant KD.
CI  - (c) Copyright: Yonsei University College of Medicine 2018
FAU - Jang, Hyejin
AU  - Jang H
AUID- ORCID: 0000-0002-8358-494X
AD  - Department of Pediatrics, Yonsei University College of Medicine, Severance 
      Children's Hospital, Seoul, Korea.
FAU - Kim, Kyu Yeun
AU  - Kim KY
AD  - Department of Pediatrics, Yonsei University College of Medicine, Severance 
      Children's Hospital, Seoul, Korea.
FAU - Kim, Dong Soo
AU  - Kim DS
AUID- ORCID: 0000-0002-3270-506X
AD  - Department of Pediatrics, Yonsei University College of Medicine, Severance 
      Children's Hospital, Seoul, Korea. dskim6634@yuhs.ac.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Yonsei Med J
JT  - Yonsei medical journal
JID - 0414003
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Steroids)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - C-Reactive Protein/analysis
MH  - Child
MH  - Child, Preschool
MH  - Coronary Vessels/pathology
MH  - Demography
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Infant
MH  - Male
MH  - Methotrexate/administration & dosage/*therapeutic use
MH  - Mucocutaneous Lymph Node Syndrome/blood/*drug therapy
MH  - Retrospective Studies
MH  - Steroids/therapeutic use
MH  - Treatment Outcome
PMC - PMC5725347
OTO - NOTNLM
OT  - Kawasaki disease
OT  - coronary artery lesion
OT  - immunoglobulin-resistant Kawasaki disease
OT  - methotrexate
COIS- The authors have no financial conflicts of interest.
EDAT- 2017/12/08 06:00
MHDA- 2018/03/10 06:00
PMCR- 2018/01/01
CRDT- 2017/12/08 06:00
PHST- 2017/07/07 00:00 [received]
PHST- 2017/10/13 00:00 [revised]
PHST- 2017/10/14 00:00 [accepted]
PHST- 2017/12/08 06:00 [entrez]
PHST- 2017/12/08 06:00 [pubmed]
PHST- 2018/03/10 06:00 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 59.113 [pii]
AID - 10.3349/ymj.2018.59.1.113 [doi]
PST - ppublish
SO  - Yonsei Med J. 2018 Jan;59(1):113-118. doi: 10.3349/ymj.2018.59.1.113.